This is a working overview of Deamidation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by HPLC area | Higher grades are also offered |
| Primary analytical method | Reversed-phase HPLC, UV detection | Frequently paired with mass spectrometry |
| Confirmatory technique | Electrospray mass spectrometry | Observed mass compared with theory |
| Storage temperature | Minus 20 degrees Celsius, dry powder | Sealed, desiccated, protected from light |
| Solution handling | Prepare fresh before use | Hydrolysis proceeds in aqueous media |
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
==== Avengers: Damage Control ==== In October 2019, Marvel Studios and ILMxLAB announced the virtual reality experience Avengers: Damage Control. The experience was available for a limited time starting in mid-October 2019 at select Void VR locations. Avengers: Damage Control sees players taking control of one of Shuri's Emergency Response Suits–which combine Wakandan and Stark Industries technologies–to defeat a threat alongside Doctor Strange, Ant-Man, and the Wasp. Letitia Wright, Benedict Cumberbatch, Paul Rudd, and Evangeline Lilly all reprise their MCU roles, while Ross Marquand voices Ultron, replacing James Spader. The experience was extended to the end of 2019.
17O (n,α) → 14C Some tritium removal facilities make a point of replacing the oxygen of the water with natural oxygen (mostly 16O) to give the added benefit of reducing 14C production. The isotope was first hypothesized and subsequently imaged by Patrick Blackett in Rutherford's lab in 1925: It was a product out of the first man-made transmutation of 14N and 4He2+ conducted by Frederick Soddy and Ernest Rutherford in 1917–1919. Its presence in Earth's atmosphere was later detected in 1929 by Giauque and Johnson in absorption spectra, demonstrating its natural existence.
== History == Efforts to isolate the active ingredients in cannabis were made in the 19th century. Cannabidiol was studied in 1940 from Minnesota wild hemp and Egyptian Cannabis indica resin. The chemical formula of CBD was proposed from a method for isolating it from wild hemp. Its structure and stereochemistry were determined in 1963.
==== Academic honesty ==== Generative AI can be used to generate and modify academic prose, paraphrase sources, and translate languages. The use of generative AI in a classroom setting has challenged traditional definitions of academic plagiarism, leading to a "cat-and-mouse" dynamic between students using AI and institutions attempting to detect it. In the immediate wake of ChatGPT's release, many school districts and universities issued temporary bans on the technology, though many institutions have since moved toward policies of managed integration. However, the implementation of these policies often lacks clarity. Research suggests that the burden of interpreting "acceptable use" frequently falls on individual students and teachers, creating an environment where academic honesty becomes difficult to define and enforce. A commonly proposed use for teachers is grading and giving feedback. Companies like Pearson and ETS use AI to score grammar, mechanics, usage, and style, but not for main ideas or overall structure. The National Council of Teachers of English stated that machine scoring makes students feel their writing is not worth reading. AI scoring has also given unfair results for students from different ethnic backgrounds.
Sources: en.wikipedia.org
== Entrepreneurship == Mrksich has been an active entrepreneur over the past twenty years. He co-founded SAMDI Tech in 2011, which uses his label-free assay technology to perform high throughput screens for pharmaceutical companies. SAMDI Tech entered into a partnership with Charles River Laboratories in 2018 and was purchased by CRL in 2023. Mrksich also co-founded WMR Biomedical in 2008, with George Whitesides and Carmichael Roberts to develop resorbable stent materials; this company was renamed Lyra Therapeutics and had an IPO in 2020 (NASDAQ LYRA) and has drug-eluting stents in clinical trials for ear, nose and throat disease, including chronic rhinosinusitis. Mrksich has recently founded ModuMab Therapeutics, which applies his megamolecule technology to creating antibody mimics for a broad range of diseases.
The patient is immunocompromised (for example, in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not responded to first line antibiotics; The disease might be dangerous to other patients, and the patient might have to be isolated
We used to read this same atavistic proclamation by the hellish light of burning Sarajevo, and now we glimpse it again through the flames of the blazing U.S. Embassy in Belgrade, and by the glare of similar but less dramatic arsons set by Serbs in ski masks in northern Kosovo itself. But it needs to be understood that "Serbia" itself has lost nothing and has nothing to complain about. With the independence of Kosovo, the Yugoslav idea is finally and completely dead, but it was Serbian irredentism that killed the last vestige of that idea, and it is to that account that the whole cost ought to be charged. Forget all the nonsense that you may have heard about Kosovo being "the Jerusalem" of Serbia. It may contain some beautiful and ancient Serbian and Serbian Orthodox cultural sites, but it is much more like Serbia's West Bank or Gaza, with a sweltering, penned-up, subject population who were for generations treated as if they were human refuse in the land of their own birth. Nobody who has spent any time in the territory, as I did during and after the eviction of the Serb militias, can believe for a single second that any Kosovar would ever again submit to rule from Belgrade. It's over.
Sources: en.wikipedia.org
The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.
The dry powder is commonly kept at minus twenty degrees Celsius, desiccated and away from light. Solutions are generally prepared fresh because they break down faster than the solid form.
Tandem mass spectrometry or enzymatic peptide mapping can establish residue order. A single intact mass value indicates composition and molecular weight but not always the precise arrangement of residues.
The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.